Matthew Germinaro

Statistics

Publications

Citations

1.3K

H-Index

Active since

2016

Affiliations

Janssen (United States)(Current)

Icahn School of Medicine at Mount Sinai

Western University

Hospital Clínic de Barcelona

University of California San Diego

Matthew Germinaro is an author at Janssen (United States) specializing in pharmacotherapy, inflammatory bowel disease, and gastrointestinal inflammation.

Publications per year

2016–2025

Publications

Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels

Leif Bjermer, Catherine Lemière, Jorge Máspero et al. · CHEST Journal · 2016 · 426 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan, Bruce E. Sands, William J. Sandborn et al. · The Lancet. Gastroenterology & hepatology · 2023 · 224 citations

Pharmacy, Clinical Sciences, Pharmacotherapy +12

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

William J. Sandborn, Geert D’Haens, Walter Reinisch et al. · Gastroenterology · 2022 · 198 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin et al. · Gastroenterology · 2023 · 92 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps

Steven F. Weinstein, Rohit Katial, Philip G. Bardin et al. · The Journal of Allergy and Clinical Immunology In Practice · 2018 · 88 citations

Medicine, Otolaryngology, Pharmacotherapy +17

1–5 of 17